Local pain at injection site

Age groups

MRVAC

Control

1 - 2 years

9/280 (3.2%) (95% CI; 1.1% - 5.23%)

5/140 (3.6%) (95% CI; 0.51% - 6.7%)

2 - 18 years

0/112

0/56

18 - 45 years

1/112 (0.9%) (95% CI; 0% - 2.7%)

0/56

Total

10/504 (2.0%) (95% CI; 0.8% - 3.2%)

5/252 (2.0%) (95% CI; 0.3% - 3.7%)

Eruption at injection site

Age groups

MRVAC

Control

1 - 2 years

13/280 (4.6%) (95% CI; 2.2% - 7.1% )

15/140 (10.7%) (95% CI; 5.6% - 15.8%)

2 - 18 years

1/112 (0.9%) (95% CI; 0% - 2.7%)

2/56 (3.6%) (95% CI; 0% - 8.5%)

18 - 45 years

1/112 (0.9%) (95% CI; 0% - 2.7%)

0/56

Total

15/504 (3.0%) (95% CI; 1.5% - 4.5%)

17/252 (6.7%) (95% CI; 3.6% - 9.8%)

Swelling at injection site

Age groups

MRVAC

Control

1 - 2 years

2/280 (0.7%) (95% CI; 0% - 1.7%)

2/140 (1.4%) (95% CI; 0% - 3.4%)

2 - 18 years

1/112 (0.9%) (95% CI; 0% - 2.7%)

1/56 (1.8%) (95% CI; 0% - 5.3%)

18 - 45 years

1/112 (0.9%) (95% CI; 0% - 2.7%)

2/56 (3.6%) (95% CI; 0% - 8.48%)

Total

4/504 (0.8%) (95% CI; 0% - 1.6%)

5/252 (1.9%) (95% CI; 0.2% - 3.6%)